◀ Back to MDM2

MDM2 — RPL11

Pathways - manually collected, often from reviews:

• NCI Pathway Database p53 pathway: RPL5 (RPL5) → MDM2/RPL5/RPL11/RPL23 complex (RPL5-MDM2-RPL11-RPL23) (modification, collaborate)
  Lohrum et al., Cancer Cell 2003, Zhang et al., Mol Cell Biol 2003, Dai et al., J Biol Chem 2004, Dai et al., Mol Cell Biol 2004*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database p53 pathway: MDM2 (MDM2) → RPL11 (RPL11) (modification, collaborate) Lohrum et al., Cancer Cell 2003, Zhang et al., Mol Cell Biol 2003, Dai et al., J Biol Chem 2004, Dai et al., Mol Cell Biol 2004*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database p53 pathway: MDM2 (MDM2) → MDM2/RPL5/RPL11/RPL23 complex (RPL5-MDM2-RPL11-RPL23) (modification, collaborate)
  Lohrum et al., Cancer Cell 2003, Zhang et al., Mol Cell Biol 2003, Dai et al., J Biol Chem 2004, Dai et al., Mol Cell Biol 2004*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database p53 pathway: RPL11 (RPL11) → MDM2/RPL5/RPL11/RPL23 complex (RPL5-MDM2-RPL11-RPL23) (modification, collaborate)
  Lohrum et al., Cancer Cell 2003, Zhang et al., Mol Cell Biol 2003, Dai et al., J Biol Chem 2004, Dai et al., Mol Cell Biol 2004*
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database p53 pathway: RPL23 (RPL23) → MDM2/RPL5/RPL11/RPL23 complex (RPL5-MDM2-RPL11-RPL23) (modification, collaborate)
  Lohrum et al., Cancer Cell 2003, Zhang et al., Mol Cell Biol 2003, Dai et al., J Biol Chem 2004, Dai et al., Mol Cell Biol 2004*
  Evidence: mutant phenotype, physical interaction

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Bind Interaction: MDM2 — RPL11 Lohrum et al., Cancer Cell 2003
• IRef Bind_translation Interaction: MDM2 — RPL11 (two hybrid) Lohrum et al., Cancer Cell 2003
• IRef Bind_translation Interaction: MDM2 — RPL11 (coimmunoprecipitation) Lohrum et al., Cancer Cell 2003
• IRef Bind_translation Interaction: MDM2 — RPL11 (unspecified method) Lohrum et al., Cancer Cell 2003
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Lohrum et al., Cancer Cell 2003
• IRef Biogrid Interaction: MDM2 — RPL11 (direct interaction, pull down) Lohrum et al., Cancer Cell 2003
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Deisenroth et al., Mol Cell Biol 2010*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Frum et al., J Proteome Res 2007
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Sun et al., J Biol Chem 2007*
• IRef Biogrid Interaction: MDM2 — RPL11 (colocalization, biochemical) Sun et al., J Biol Chem 2007*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Bursać et al., Proc Natl Acad Sci U S A 2012
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Donati et al., Oncogene 2011*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Gilkes et al., EMBO J 2006*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Cui et al., Oncogene 2014*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Ebina et al., PloS one 2013*
• IRef Biogrid Interaction: MDM2 — RPL11 (direct interaction, two hybrid) Wang et al., Molecular systems biology 2011
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Zhang et al., Mol Cell Biol 2003
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Dai et al., Mol Cell Biol 2008*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Dai et al., J Biol Chem 2006*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Dai et al., Mol Cell Biol 2004*
• IRef Biogrid Interaction: MDM2 — RPL11 (colocalization, biochemical) Dai et al., Mol Cell Biol 2004*
• IRef Biogrid Interaction: MDM2 — RPL11 (direct interaction, pull down) Dai et al., J Biol Chem 2004
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Dai et al., J Biol Chem 2004
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Yu et al., Nucleic Acids Res 2011*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Sasaki et al., Nat Med 2011*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Sun et al., J Biol Chem 2010*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Jin et al., Mol Cell Biol 2004*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Lindström et al., Mol Cell Biol 2007*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Horn et al., Oncogene 2008*
• IRef Biogrid Interaction: MDM2 — RPL11 (association, biochemical) Zhang et al., J Biol Chem 2011*
• IRef Biogrid Interaction: MDM2 — RPL11 (direct interaction, pull down) Zhang et al., J Biol Chem 2011*
• IRef Biogrid Interaction: MDM2 — RPL11 (physical association, affinity chromatography technology) Zhang et al., J Biol Chem 2011*
• IRef Hprd Interaction: Complex of 17 proteins (in vivo) Gilkes et al., EMBO J 2006*
• IRef Hprd Interaction: RPL11 — MDM2 (two hybrid) Lohrum et al., Cancer Cell 2003, Zhang et al., Mol Cell Biol 2003, Gilkes et al., EMBO J 2006*
• IRef Hprd Interaction: RPL11 — MDM2 (in vivo) Lohrum et al., Cancer Cell 2003, Zhang et al., Mol Cell Biol 2003, Gilkes et al., EMBO J 2006*
• IRef Hprd Interaction: RPL11 — MDM2 (in vitro) Lohrum et al., Cancer Cell 2003, Zhang et al., Mol Cell Biol 2003, Gilkes et al., EMBO J 2006*
• IRef Intact Interaction: Complex of 11 proteins (association, anti bait coimmunoprecipitation) Frum et al., J Proteome Res 2007
• IRef Intact Interaction: Complex of RPL11-MDM2 (association, anti bait coimmunoprecipitation) Kapoor et al., FEBS Lett 2013*
• IRef Intact Interaction: MDM2 — RPL11 (physical association, anti bait coimmunoprecipitation) Gilkes et al., EMBO J 2006*
• IRef Intact Interaction: MDM2 — RPL11 (physical association, two hybrid) Chen et al., Oncogene 2007*
• IRef Intact Interaction: MDM2 — RPL11 (physical association, anti tag coimmunoprecipitation) Sundqvist et al., EMBO Rep 2009*
• IRef Intact Interaction: MDM2 — RPL11 (physical association, two hybrid array) Wang et al., Molecular systems biology 2011
• IRef Intact Interaction: MDM2 — RPL11 (physical association, two hybrid) Wang et al., Molecular systems biology 2011
• IRef Intact Interaction: Complex of MDM2-RPL11-RPL5-RPL11-RPL5-MDM2 (association, anti bait coimmunoprecipitation) Donati et al., Oncogene 2011*
• IRef Ophid Interaction: MDM2 — RPL11 (aggregation, interologs mapping) Brown et al., Bioinformatics 2005

Text-mined interactions from Literome

Lohrum et al., Cancer Cell 2003 : Regulation of HDM2 activity by the ribosomal protein L11
Zhang et al., J Biol Chem 2011 : These results provide the first line of evidence for the specific interaction between RPL11 and the zinc finger of MDM2 via hydrophilic residues as well as a molecular foundation for better understanding RPL11 inhibition of MDM2 function
Donati et al., Cell reports 2013 : Recently, we demonstrated that RPL5 and RPL11 act in a mutually dependent manner to inhibit Hdm2 and stabilize p53 following impaired ribosome biogenesis